Related Experiment Video

Updated: Apr 6, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.3K

Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance

Eva Martinez-Balibrea1, Anna Martínez-Cardús2, Alba Ginés3

  • 1Medical Oncology Service, Catalan Institute of Oncology (ICO), Hospital Germans Trias i Pujol, Badalona, Barcelona, Catalonia, Spain. Health Sciences Research Institute of the Germans Trias i Pujol Foundation (IGTP). Badalona, Catalonia, Spain. embalibrea@iconcologia.net.

Molecular Cancer Therapeutics
|July 18, 2015
PubMed

Insights

Oxaliplatin is a key drug for colorectal cancer, but resistance limits its effectiveness. Understanding resistance mechanisms is crucial for improving cancer treatments.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Oxaliplatin is a crucial platinum-based chemotherapy agent widely used for colorectal cancer treatment.
  • It is also investigated for pancreatic and gastric cancers, highlighting its broad applicability.
  • Tumor resistance to oxaliplatin remains a significant challenge, leading to treatment failure.

Purpose of the Study:

  • To review recent advancements in understanding oxaliplatin resistance mechanisms in tumors.
  • To identify key molecular pathways involved in both intrinsic and acquired resistance.
  • To provide insights for developing strategies to overcome oxaliplatin resistance.

Main Methods:

  • Literature review of recent scientific publications.
  • Focus on molecular mechanisms of resistance.
  • Analysis of pathways including drug transport, detoxification, DNA damage response, cell death, and epigenetics.

Main Results:

  • Resistance involves complex mechanisms affecting drug uptake and cellular processing.
  • Alterations in DNA damage response and repair pathways significantly contribute to resistance.
  • Dysregulation of apoptotic and non-apoptotic cell death pathways plays a role.
  • Epigenetic modifications are increasingly recognized as drivers of oxaliplatin resistance.

Conclusions:

  • Oxaliplatin resistance is multifactorial, involving cellular transport, detoxification, DNA repair, and cell death evasion.
  • Epigenetic factors represent a promising area for further research in overcoming resistance.
  • A comprehensive understanding of these mechanisms is essential for optimizing oxaliplatin-based therapies.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.3K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.3K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K